Inventia Life Science

Matrix stiffness does more than shape structure: it can change how breast cancer cells resist chemotherapy. Download the UNSW Sydney poster on how ECM mechanics drive stemness and drug resistance in 3D breast cancer models.

Building immune–tumor and tumor–stromal models without an internal 3D development program. Tunable matrices, immune-cell infiltration and co-culture integrity, at a scale you can actually run.

Sponsor requirements change; your assay platform shouldn't have to. Reproducible 3D models across multiple cell and disease contexts, with documentation and rapid transfer between projects.

Similar CEACAM5 expression, very different ADC response. Patient-derived colorectal tumoroid models were used to compare an antibody-drug conjugate across two CRC subtypes, with results target expression alone wouldn't predict.

Patient-derived 3D models, drug response testing and multi-omics in one framework. A rapid and scalable approach to evaluating precision medicine strategies against biologically relevant models.

Patient-derived colorectal models combined with 3D drug response testing, RNA sequencing and proteomics, turning a resistance phenotype into a testable next step.